PMGC Plans to Acquire 76% Controlling Interest in Arizona Company
PMGC announced that it has entered into a non-binding letter of intent to acquire a 76% controlling interest in a privately held, Arizona based U.S.-based precision machining and contract manufacturing company. The transaction would result in the target's existing owners retaining a 24% minority interest following closing. Based on unaudited financial information provided to PMGC by the target, the target generated approximately $5.46M in revenue and approximately $1.05M in EBITDA for fiscal year 2025. The LOI provides PMGC with a defined exclusivity period, during which the target and its representatives may not solicit or negotiate competing offers, providing the company with a protected window to complete confirmatory due diligence and negotiate definitive documentation. Founded in 2006, the target is a precision machining contract manufacturer specializing in high-tolerance, multi-axis CNC machining, including Swiss machining, multi-axis milling, and multi-tasking turning of complex metal and plastic components. The target has operated for nearly two decades and machines a broad range of materials, including aluminum, brass, stainless steel, titanium, Inconel, and engineered plastics, supported by value-added capabilities, such as laser marking, ultrasonic cleaning, microscopic deburring and microblasting, coordinating measuring machine inspection, and performing light assembly. Under the terms of the LOI, PMGC would acquire a 76% controlling interest in the target for cash, with the target's existing owners retaining the remaining 24% interest. The proposed consideration for this interest is subject to confirmatory due diligence. The LOI is non-binding, except with respect to customary provisions regarding exclusivity, confidentiality, expenses, and governing law, and completion of the transaction is subject to customary closing conditions, including the negotiation and execution of a definitive purchase agreement, the completion of a financial statement audit of the target, and applicable board and regulatory approvals. There can be no assurance that the transaction will be completed on the terms described herein, or at all. The company said, "We are currently engaging our auditors to begin a 2-year historical financial audit and interim review of 2026 financial records of the target-to-target completion and closing before Q4 2026. We cannot assure that the US GAAP audit can be completed and the closing will occur, or that audited financial statements will not significantly differ from the unaudited financial statements provided by the Target to us."
Trade with 70% Backtested Accuracy
Analyst Views on ELAB
About ELAB
About the author

- Strategic Merger: PMGC Holdings announced the merger of AGA Precision Systems into A&B Aerospace, aiming to streamline its aerospace precision manufacturing platform by consolidating two related businesses, thereby enhancing operational efficiency and resource sharing.
- Continued Operations: Post-merger, AGA will cease to exist as a separate legal entity, while A&B Aerospace will continue to operate under the AGA name to maintain customer and contract continuity, ensuring that customer relationships remain intact.
- Resource Sharing: Both manufacturing sites are expected to continue operations, with the combined business sharing personnel, facilities, and equipment, which is anticipated to reduce duplicative governance and administrative overhead, enhancing overall operational flexibility.
- Enhanced Customer Coverage: PMGC expects the combined structure to support greater customer coverage and service capabilities, further solidifying its market position in the aerospace and defense sectors.
- Can-Fite Clinical Results: Can-Fite BioPharma's Phase 2a study with 20 patients achieved its primary safety endpoint, showing a median overall survival exceeding five months in heavily pretreated patients, which is expected to propel the company into a Phase 2b combination study with chemotherapy to further validate efficacy.
- NeOnc Regulatory Progress: NeOnc Technologies is set to release Phase 2a data from its NEO100-01 study, which has received multiple FDA designations, providing significant regulatory advantages, while its recent IND approval in Abu Dhabi will expand its international clinical trial scope.
- PMGC AI Drug Discovery: PMGC Holdings' NorthStrive Biosciences partnership with Yuva Biosciences has identified several small-molecule candidates using the MitoNova™ AI platform, demonstrating potential muscle health benefits, which is expected to advance its EL-22 program further.
- Market Focus: Biotechnology investors are gravitating towards companies capable of generating multiple value-driving catalysts, with Can-Fite, NeOnc, and PMGC's upcoming clinical data, regulatory milestones, and AI drug discovery advancements indicating a critical observation period in the coming months.
- Significant AI Achievements: Yuva Biosciences' MitoNova™ AI platform successfully identified four small-molecule candidates that significantly increased ANT1 protein expression in primary human skeletal muscle cells, indicating their potential role in muscle energy metabolism and offering new therapeutic avenues for muscle health and metabolic stress applications.
- Outstanding Candidate Performance: In the Phase III study, candidates C1, C2, C3, and C4 demonstrated statistically significant increases in ANT1 expression, with C2 showing a 50% increase, C4 at 48%, C1 at 46%, and C3 achieving a 29% increase at the highest dose, highlighting their promising dose-dependent effects.
- Next Development Steps: Following the positive Phase III results, Yuva Biosciences recommended advancing the four validated candidates into a more mature skeletal muscle model for confirmatory testing, aiming to further validate ANT1 induction and mitigate risks in subsequent development, reflecting the company's confidence in future product advancements.
- Deepening Strategic Collaboration: The study results not only validate Yuva Biosciences' AI-driven drug discovery capabilities but also provide crucial support for NorthStrive Biosciences' muscle preservation development strategy, signaling potential market opportunities in aging-related therapies.
- Patent Application Expansion: PMGC Holdings' wholly-owned subsidiary NorthStrive has filed two new patent applications for human pharmaceutical uses of EL-22 and EL-32 aimed at preserving lean muscle mass during GLP-1 and obesity-related weight loss, marking a strategic shift from animal health to human applications.
- New Drug Combinations: The new applications include the co-administration of EL-22 or EL-32 with apelin or ursolic acid, compounds associated with muscle support, addressing the growing demand in the obesity treatment market and potentially opening new revenue streams for the company.
- Market Demand Response: With the rapid adoption of GLP-1 and related weight loss therapies, PMGC believes that the need for muscle preservation will become a critical area of product development, enhancing the company's competitiveness in the biopharmaceutical market.
- Technological Innovation: The new patent applications encompass various pharmaceutical delivery forms, including oral, injectable, and topical, showcasing the company's innovative capabilities in muscle preservation, which is expected to lay the groundwork for future clinical applications.
- Growing Market Demand: PMGC's subsidiaries A&B Aerospace, SVM Machining, and AGA Precision Systems are leveraging advanced precision manufacturing capabilities to meet the rapidly expanding space economy, with projections indicating the global space economy could reach $1.8 trillion by 2035, highlighting significant market potential.
- Technical Certification Advantage: These companies possess ITAR registration and AS9100 certification, ensuring their products meet high standards required in aerospace and defense sectors, thereby enhancing their competitiveness in space exploration and related markets.
- Established Customer Base: Prior to acquisition, PMGC's operating companies had built strong relationships with notable clients such as SpaceX and Moog, with space-related projects accounting for 5.7% of total revenue over the past two years, laying a solid foundation for future growth.
- Significant Growth Opportunities: PMGC plans to expand its market share in space exploration, satellite, and launch systems by leveraging existing operating companies and technical expertise, capitalizing on largely untapped market opportunities to drive long-term growth.
- Patent Licensing Agreement: NorthStrive Defense Tech has entered into a binding patent licensing agreement covering U.S. Patent No. 12,291,334 for multi-domain drone payload technology, aimed at enhancing transport efficiency in the aerospace and defense sectors, which is expected to bolster the company's competitive position in the relevant markets.
- Technological Advantage: This technology enables drones to autonomously transport cable-suspended payloads across air and water, utilizing buoyancy-assisted transport to significantly improve payload efficiency over traditional air-only drone systems, addressing the need for concealed transport in complex maritime environments.
- R&D Plan: The accompanying sponsored research program will last for 12 months, focusing on developing a small payload prototype and conducting empirical testing to ensure the feasibility and stability of the technology, thereby laying the groundwork for future commercialization and advancing the company's growth in the defense market.
- Market Outlook: With advancements in unmanned undersea vehicle technology by the U.S., U.K., and Australia, NorthStrive Defense Tech believes its patented technology is well-positioned in a defense market increasingly focused on multi-domain unmanned systems and maritime autonomy, potentially leading to more commercial opportunities in the future.







